
...BIBLIOGRAPHY...

- Alderman MH, Schoenbaum EE. Detection and treatment of hypertension at the work site. *N Engl J Med* 1975;293:65-68.
- Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: Secular trends in Rochester, Minnesota through 1989. *Stroke* 1996;27:373-380.
- Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. *Hypertension* 1995;25:305-313.
- Dustan HP, Roccella EJ, Garrison HH. Controlling hypertension: A research success story. *Arch Intern Med* 1996;156:1926-1935.
- Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. *Am J Cardiol* 1997;79:431-435.
- Gradman AH, Lewin A, Bowling BT, et al, for the Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. Comparative effects of candesartan, cilxetil and losartan in patients with systemic hypertension. *Heart Dis* 1999;1:52-57.
- Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial. *Lancet* 1999;353:611-616.
- Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. *JAMA* 1996;275:1557-1562.
- Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition of diabetic nephropathy. *N Engl J Med* 1993;329:1456-1462.
- Luepker RV, McGovern PG, Sprafka JM, Shahar E, Doliszny KM, Blackburn H. Unfavorable trends in the detection and treatment of hypertension: The Minnesota Heart Survey [abstract]. *Circulation* 1995;91:938.
- MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. *Lancet* 1990;335:765-773.
- Managed Care Organization (MCO) Accreditation. Final HEDIS effectiveness of care benchmarks and thresholds for accreditation '99. NCQA Web site. Available at: www.NCQA.org/docs/HEDIS/benchmk.doc. Accessed January 26, 2000.
- Meissner I, Whisnant JP, Shaps S, et al. Stroke prevention: assessment of risk in a community; The SPARC Study, I: Blood pressure trends, treatment and control [abstract]. *Ann Neurol* 1997;42:433.
- Messerli F, Grossman E, Goldbourt U. Are beta blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. *JAMA* 1998;279:1903-1907.
- Mosterd A, D'Agostino RB, Silbershatz H, et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. *N Engl J Med* 1999;340:1221-1227.
- National Center for Health Statistics. *Health, United States, 1996*. Hyattsville MD: US Public Health Service; 1997.
- Perera GA. Hypertensive vascular disease. Description and natural history. *J Chronic Dis* 1955;1:33-42.
- Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement (SAVE) trial. *N Engl J Med* 1992;327:669-677.
- Psaty BM, Smith NL, Siscovik DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. *JAMA* 1997;277:739-745.
- SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 1991;265:3255-3264.

... BIBLIOGRAPHY ...

- Staessen JA, Fagard R, Thijs L, et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. *Lancet* 1997;350:757-764.
- Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care* 1998;21:597-603.
- The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med* 2000;342:145-153.
- The Sixth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. *Arch Intern Med* 1997;157:2413-2446.
- US Renal Data System. *USRDS 1997 Annual Report*. Washington, DC: US Dept of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Disease; 1997.

... NOTES ...